Sun Dips Toe Into Vaccines With Dengvaxia Challenge
Executive Summary
India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.
You may also be interested in...
Sun Evaluating Plant-Based Candidates To Treat Zika
Sun Pharma expects to study plant-based drug candidates to treat the Zika virus in a tie-up with India’s state-run National Institute of Virology, as part of a wider initiative to test new medicines to act against mosquito-borne diseases.
Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.
Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.